

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

BACKGROUND

Reference is made to the announcement of the Company dated March 23, 2026 in relation to the subscription of wealth management product offered by PDB in the total principal amount of RMB100 million (the “**PDB March Subscription**”).

SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

The Board announces that on April 29, 2026, in order to effectively utilize its idle funds, the Company entered into subscription agreements with PDB to subscribe for certain wealth management products offered by PDB, the principal terms of which are set out below.

The Company agreed to subscribe for wealth management products offered by PDB with a principal amount of RMB100 million and a maturity date of October 29, 2026 (the “**PDB Subscription I**”), details of which are set out below:

Product name	Confirmation date of subscription	Maturity date	Principal amount of subscription	Expected yield of the product (per annum)	Product type	Risk level of the product
Liduoduo Corporate Stable Profit 26JG7131 (Three Level Bullish) RMB Public Structured Deposit (利多多公司穩利26JG7131期(三層看漲)人民幣對公結構性存款)	April 29, 2026	October 29, 2026	RMB100 million	The product has a guaranteed yield of 0.95% and a floating yield of 0% or 0.85% (mid-range floating yield) or 1.05% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)

The Company agreed to subscribe for wealth management products offered by PDB with a principal amount of RMB100 million and a maturity date of November 6, 2026 (the “**PDB Subscription II**”), details of which are set out below:

Product name	Confirmation date of subscription	Maturity date	Principal amount of subscription	Expected yield of the product (per annum)	Product type	Risk level of the product
Liduoduo Corporate Stable Profit 26JG7156 (Three Level Bullish) RMB Public Structured Deposit (利多多公司穩利26JG7156期(三層看漲)人民幣對公結構性存款)	May 6, 2026	November 6, 2026	RMB100 million	The product has a guaranteed yield of 0.95% and a floating yield of 0% or 0.85% (mid-range floating yield) or 1.05% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)

The Company agreed to subscribe for wealth management products offered by PDB with a principal amount of RMB70 million and a maturity date of August 6, 2026 (the “**PDB Subscription III**”), details of which are set out below:

Product name	Confirmation date of subscription	Maturity date	Principal amount of subscription	Expected yield of the product (per annum)	Product type	Risk level of the product
Liduoduo Corporate Stable Profit 26JG7143 (Three Level Bullish) RMB Public Structured Deposit (利多多公司穩利26JG7143期(三層看漲)人民幣對公結構性存款)	May 6, 2026	August 6, 2026	RMB70 million	The product has a guaranteed yield of 0.70% and a floating yield of 0% or 0.70% (mid-range floating yield) or 0.90% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)

BASIS OF CONSIDERATION

The Board confirms that the consideration for each of PDB Subscription I, PDB Subscription II and the PDB Subscription III was determined in accordance with commercial terms negotiated at arm’s length between the Company and PDB, taking into account (i) the then surplus cash available to the Company for capital management; (ii) the expected investment return and terms of the subscriptions; and (iii) prevailing market interest rates and practices. The subscriptions were financed by the Company’s own funds (other than the proceeds from the initial public offering).

INFORMATION OF THE PARTIES

Qyuns

The Company was incorporated in the PRC in 2015 and its shares are listed on the Main Board of the Stock Exchange (stock code: 2509). The Company is a biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and mature commercial-scale in-house manufacturing capacity. The Company's product pipeline covers four major areas in the autoimmune and allergic disease field, namely, skin, rheumatic, respiratory and digestive diseases.

PDB

To the best knowledge of the Directors, PDB is a commercial bank principally engaged in banking services and its shares are listed on the Shanghai Stock Exchange (stock code: 600000).

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, based on the public information available to the Company, PDB and its ultimate beneficial owners are third parties independent of the Company and its connected persons.

REASONS FOR AND BENEFITS OF THE SUBSCRIPTION

The Company made the subscriptions for the purpose of capital management to maximize the use of its idle funds in order to achieve a balanced return while maintaining a high level of liquidity and a low level of risk. Taking into account, among other things, the low level of risk and the expected yield of the wealth management product, the Company is of the view that the subscriptions will provide the Group with a better yield than those of the deposits generally offered by commercial banks and will enhance the overall profitability of the Company. The Company has monitored and managed the subscriptions closely and effectively and will continue to monitor and manage the subscriptions closely and effectively.

Having considered that the subscriptions are principal-guaranteed floating-yield bank structured deposits which have been carefully assessed and categorized as of relatively low risk and with reference to similar products in the market and their general yields, the Board is of the view that the terms of the subscriptions are fair and reasonable and in the best interests of the Company and its Shareholders as a whole. The Group has implemented adequate and appropriate internal control procedures to ensure that the subscriptions will not affect the working capital or operations of the Group and that such investments will be made under the principle of safeguarding the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As the PDB March Subscription, PDB Subscription I, PDB Subscription II and the PDB Subscription III are each subscribed from the same bank (i.e. PDB), are similar in nature and are made within 12 months, they will be aggregated for the purpose of calculating the highest applicable percentage ratio in accordance with Rule 14.22 of the Listing Rules as if they were one single transaction. As one or more of the applicable percentage ratios, in respect of the aggregated subscription amount of the PDB March Subscription, PDB Subscription I, PDB Subscription II and the PDB Subscription III at the relevant period, exceed 5% but are less than 25%, the PDB Subscription I, PDB Subscription II and the PDB Subscription III, when aggregated with the PDB March Subscription constitute discloseable transactions of the Company under the Listing Rules, and are subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

“Board”	the board of Directors of the Company
“Company”	Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司), a limited liability company incorporated in the PRC in 2015, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2509)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PDB”	Shanghai Pudong Development Bank Co., Ltd. (上海浦東發展銀行股份有限公司)
“PDB Subscription I”	subscription by the Company for wealth management products (26JG7131) offered by PDB with a principal amount of RMB100 million and a maturity date of October 29, 2026
“PDB Subscription II”	subscription by the Company for wealth management products (26JG7156) offered by PDB with a principal amount of RMB100 million and a maturity date of November 6, 2026
“PDB Subscription III”	subscription by the Company for wealth management products (26JG7143) offered by PDB with a principal amount of RMB70 million and a maturity date of August 6, 2026
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excludes the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC

“Shareholder(s)” shareholders of the Company

“Stock Exchange” The Stock Exchange of Hong Kong Limited

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, April 29, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive directors.